Deregulation of the histone H3K9 dimethylation landscape suppresses Wnt signaling in embryonal rhabdomyosarcoma
Taneja, R.; Pal, A.; Leung, J. Y.; Ang, G. C. K.; Rao, V. K.; Pignata, L.; Lim, H. J.; Hebrard, M.; Chang, K. T.; Lee, V. K.; Guccione, E.
Show abstract
The Wnt signaling pathway is down-regulated in embryonal rhabdomyosarcoma (ERMS) and contributes to the block of myogenic differentiation. Epigenetic mechanisms leading to its suppression are unknown and could pave the way towards novel therapeutic modalities. In this study, we demonstrate that the H3K9 lysine methyltransferase G9a suppresses canonical Wnt signaling by activating expression of the Wnt antagonist DKK1. Inhibition of G9a expression or activity reduced DKK1 expression and elevated canonical Wnt signaling resulting in myogenic differentiation in vitro and in vivo. Mechanistically, G9a impacted Sp1 and p300 enrichment at the DKK1 promoter in a methylation-dependent manner. The reduced tumor growth upon G9a deficiency was reversed by recombinant DKK1 or LGK974, which also inhibits Wnt signaling. Consistently, among thirteen drugs targeting chromatin modifiers, G9a inhibitors were highly effective in reducing ERMS cell viability. Together, our study demonstrates that ERMS cells are vulnerable to G9a inhibitors and suggest that targeting the G9a-DKK1-{beta}-catenin node holds promise for differentiation therapy.
Matching journals
The top 13 journals account for 50% of the predicted probability mass.